Cart
sales@molnova.com
Home - Products - Others - Other Targets - Itolizumab

Itolizumab

CAS No. 1116433-11-4

Itolizumab( —— )

Catalog No. M36716 CAS No. 1116433-11-4

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 299 Get Quote
5MG 566 Get Quote
10MG 905 Get Quote
25MG 1279 Get Quote
50MG 1730 Get Quote
100MG 2313 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Itolizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production.
  • Description
    Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.
  • In Vitro
    Itolizumab (100 μg/mL) inhibits T cell proliferation.Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs.Itolizumab (40 μg/mL) reduces CD26hiCD161+?CD8+?T cells during culture of PBMCs overnight.Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions.
  • In Vivo
    Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD).Animal Model:Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)Dosage:60 μg or 300μg Administration:Intraperitoneal injection (i.p.), prior to PBMC transplantation. Result:Decreased mortality compared to the vehicle (100% vs. 10%).
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1116433-11-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34. ?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Icaritin

    Icaritin has hormone regulation activity and cardiovascular function improvement activity. Icaritin has anticancer activity, can induce S phase arrest and apoptosis, inhibit ENKL cell proliferation.

  • Thalidomide-O-amido-...

    Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

  • N-Formyl-Met-Ala-Ser

    N-Formyl-Met-Ala-Ser is a peptide, binds to formyl peptide receptors on neutrophils.N-Formyl-Met-Ala-Ser Peptide (fMet-Ala-Ser) binds to formyl peptide receptors on neutrophils. N-Formylmethionine-containing peptides including the most potent and known member, N-formyl-Met-Leu-Phe (FMLP or fMet-Leu-Phe) stimulate human neutrophils by a receptor-dependent mechanism.

Sign In Join Free